Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 2 EP applications Mylène Audrey Séverine Quellari has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 23, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12806060

NOVEL THERAPEUTIC USE OF P75 RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/497, A61K 31/498, A61K 31/506, A61P 13/10
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
EXAMINATION IN PROGRESS
EP14784452

4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY

IPC classification:
A61K 31/519, A61P 13/12
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
GRANT OF PATENT INTENDED

Please Sign in to use this feature